Fabrazyme market seen rising to $2.35M by 2030

The Fabrazyme market is projected to grow from $1.26 million in 2025 to $2.35 million by 2030 as Fabry disease awareness, rare-disease care and enzyme replacement therapy adoption expand. North America led the market in 2025, while the report points to stronger screening, orphan-drug support and personalized medicine as key growth drivers.

Why it matters: - Fabrazyme is used to treat Fabry disease, a rare genetic disorder that can cause kidney, heart and neurological damage if untreated. - The market is small in dollar terms, but the report points to steady demand growth as diagnosis and treatment access improve. - Growth in this niche market can signal broader momentum in rare-disease care, genetic screening and orphan-drug investment.

What happened: - The Business Research Company published its Fabrazyme Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report estimates the Fabrazyme market rose from $1.26 million in 2025 to $1.43 million in 2026, a 13.6% CAGR. - The report projects the market will reach $2.35 million by 2030, implying a 13.3% CAGR over the forecast period. - North America held the largest share of the Fabrazyme market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - More information is available in the company’s sample report and the full market report.

The details: - Fabrazyme is a prescription enzyme replacement therapy for Fabry disease, which is caused by a deficiency of alpha-galactosidase A. - The enzyme shortage leads to buildup of globotriaosylceramide, or GL-3, in tissues. - That buildup can contribute to organ damage and serious complications. - Fabrazyme helps supply the missing enzyme and reduce lipid accumulation. - The report identifies limited curative options, early enzyme replacement therapy wins, better survival rates and orphan-drug incentives as drivers of recent growth. - The report expects future growth to be supported by greater awareness of Fabry disease, improved genetic screening, more specialized rare-disease clinics, treatment adherence and ongoing orphan-drug investment. - A March 2024 Gene People report cited in the release said more than 6,000 genetic conditions affect about 1 in 25 children in the UK. - Gene People also said those conditions drive about 30,000 new diagnoses each year and affect more than 2.4 million people in the UK. - The release links those diagnosis trends to higher demand for Fabrazyme. - The release also ties market growth to rising healthcare spending. - The UK Office for National Statistics reported in April 2025 that healthcare spending rose 6.5% nominally from 2023 to 2024 and 2.4% after inflation. - The release says personalized medicine is also boosting demand for Fabrazyme because it aligns treatment with a patient’s genetic profile, lifestyle and environment. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The market’s growth rate is strong, but the absolute market size remains modest, which suggests a highly specialized commercial opportunity. - The report’s emphasis on screening, specialist clinics and adherence suggests the biggest gains may come from earlier diagnosis and more consistent long-term therapy, not from a sudden expansion in the patient pool. - The repeated focus on orphan drugs and personalized medicine shows how policy support and precision treatment trends are shaping rare-disease markets.

What’s next: - The report expects continued expansion through 2030 as Fabry disease diagnosis improves and treatment pathways mature. - Further growth will likely depend on how quickly healthcare systems expand access to genetic testing, specialist care and long-term enzyme replacement therapy. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables.

The bottom line: - Fabrazyme is moving from a tiny specialty market toward steady double-digit growth, driven by rare-disease diagnosis, healthcare investment and broader adoption of precision medicine.